Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $9.6 million
Deal Type : Funding
Details : The comapany will use the received grant for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines and further optimize the hits to in vivo lead compounds during the hit-to-lead process.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $9.6 million
Deal Type : Funding
Lead Product(s) : BV100
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : BioVersys AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BV100 is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : BV100
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : BioVersys AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
